Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 860 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				XRP6976J_4001 NCT00280098


2.		PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				15 and over				Other				LAL-RI/96 NCT00494897

Last Modified: 11/1/1997


3.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410

Last Modified: 6/1/2007 First Published: 10/1/1999


4.		Phase II/III Randomized Study of Leflunomide (SU101) With Mitoxantrone and Prednisone Versus Mitoxantrone and Prednisone Alone in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.035 SUGEN-990711, NCT00004071


5.		Phase II-III Chemotherapy with BLEO/DTIC/VBL/ADR/PRED or NM/VCR/PCB/PRED Plus Radiotherapy for Advanced Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75100


6.		Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 18								SJCRH-ALL-TT-8


7.		Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								WCCC-CO-7711R NCI-D80-048-183

Last Modified: 8/10/2007


8.		Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				CCG-192P

Last Modified: 12/1/1989


9.		Phase II/III L-PAM/PRED/VCR vs VP-16/PRED/ADR for Stage II/III Myeloma (Summary Last Modified 12/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 and over								SAFR-CT-MM-2


10.		Phase II/III Combination Chemotherapy with VCR/PRED/ADR for Induction, VCR/PRED/ADR/L-ASP for Intensification, Cranial Irradiation plus Intrathecal MTX for CNS Prophylaxis, and POMP (PRED/VCR/MTX/6-MP) for Maintenance in Patients with ALL and AUL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				DFCI-77001 NCI-T83-1310D, T83-1310

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute